04/12/2013
Documents to download
Please enter your e-mail address
Last update : 09/02/2015
Management Overview
The LeukoTreat project was coordinated by Prof. Odile Boespflug-Tanguy from Université Paris Diderot - Paris 7 (UPD-P7, France), with the assistance of Estelle Tournier, from Université d'Auvergne (UDA, France), Olivier Degrand and Delphine Chatard, from France Europe Innovation (FEI, France).
During the project, Prof. Boespflug-Tanguy also benefited from the support of two specific Committees:
Finally, the Ethics Committee, chaired by LEM (France), was composed of persons independent of the scientific programme of LeukoTreat, including European experts in medical ethics, Human Sciences and Law professionals, and representatives of patients’ associations named by ELA.
Programme Overview
The LeukoTreat project aimed at promoting the development of therapeutic strategies for the largest number of leukodystrophy (LD) affected patients and further applications to more common white matter (WM) disorders and neurodegenerative diseases. To reach these objectives, LeukoTreat pursued the following actions:
For a presentation of each of these research axes, see the section Videos.